ARYx Therapeutics

About

The ARYx mission is to make proven therapies safer. By applying its retrometabolic approach to pharmaceutical discovery and development, ARYx serves patients by fundamentally improving the safety of oral therapies in large, chronic markets while maintaining their efficacy. To optimize shareholder value, ARYx’s strategy was to become a profitable company with a continuing pipeline of products, balancing risk against rewards through collaborations with pharmaceutical partners. In November 2007 the company completed an initial public offering led by Morgan Stanley and trades under the NASDAQ symbol ARYX.